MedTrace Logo

Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee

NCT03062787 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-04-21

No results posted yet for this study

Summary

It is a post-license, multicenter, randomized, single blind, controlled study comparing a single injection of Cingal® (study arm) with a single injection of Monovisc® (control arm).

Conditions

  • Osteoarthritis, Knee

Interventions

DEVICE

Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)

Intra-articular injection

DEVICE

Monovisc® (Sodium hyaluronate)

Intra-articular injection

Sponsors & Collaborators

  • Pharmascience Inc.

    lead INDUSTRY

Principal Investigators

  • Mohit Bhandari, MD, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-05
Primary Completion
2017-10-25
Completion
2017-10-25

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062787 on ClinicalTrials.gov